A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Centre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment.

Trial Profile

A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Centre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs ADX-10059 (Primary) ; Proton pump inhibitors
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2012 Actual patient number changed from 297 to 298 as reported by ClinicalTrials.gov.
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 25 Dec 2009 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top